Glomerulosclerosis, Focal Segmental - 25 Studies Found
Withdrawn |
: Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 : Focal Segmental Glomerulosclerosis : 2008-12-31 : Drug: Galactose Oral galactose, 0.2 g/kg/dose twice daily for 28 days |
Recruiting |
: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients :
|
Recruiting |
: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS : Primary Focal Segmental Glomerulosclerosis : 2012-04-05 : Biological: Rituximab Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 |
Completed |
: Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) : Glomerulosclerosis, Focal : 2005-08-24 :
|
Recruiting |
: Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS : Idiopathic Focal Segmental Glomerulosclerosis : 2015-12-15 :
|